|
In a another clinical trial involving approximately 450
subjects, Dostinex was compared with Bromocriptine in treating
hyperporlactinemia. In the eight-week, double blind trial, prolactin levels
returned to normal in 77% of subjects treated with Dostinex (0.5mg twice
weekly) compared to 59% of those treated with Bromocriptine (2.5 mg
twice-daily). Restoration of menses occurred in 77% of women treated with
Dostinex, compared to 70% of those treated with Bromocriptine .
Among subjects with galactorrhea (excessive breast milk discharge), the symptom
disappeared in 73% of those treated with Dostinex, compared to 56% of 231
subjects taking Bromocriptine .
Side Effects:
Clinical studies also showed the safety profile of Dostinex
compares favorably to Bromocriptine . Just 2% of 221 subjects taking
Dostinex discontinued treatment due to side effects during the eight-week
study, versus 60% of 231 subjects taking Bromocriptine . Nausea is
the most common side effect of both drugs. During the eight-week,
double-blinded portion of the trial, 29% of subjects experienced
nausea with Dostinex compared with 43% of those taking Bromocriptine .
Study proves:
• Dostinex is more potent in treating hyperporlactinemia than Bromocriptine
• Dostinex is more potent in treating excessive breast milk discharge than Bromocriptine
• Dostinex side-effects are milder (if any), Parlodel side-effects are more severe and probable
 |
Cabergoline (Dostinex/Cabaser) vs. Bromocriptine (Parlodel) In increasing libido (sex drive) |
A medical study by the Federico II University,
Naples, Italy
published in the European Journal Endocrinol 1998 March showed Cabergoline
(brandnames: Dostinex/Cabaser) to very potent in increasing libido
and sexual potency. The study examined the Cabergoline (Dostinex)
vs. Bromocriptine (Parlodel).
Dostinex (Cabergoline) proved superior in all respects to Parlodel (Bromocriptine ). Seventeen
males with macroprolactinoma were treated with Cabergoline or Bromocriptine
for 6 months. All patients initially suffered from libido impairment,
Ten from reduced sexual potency, and six had infertility.
Before treatment, all patients suffered from low number of erections , had a
low sperm count with oligoasthenospermia, reduced motility and rapid
progression with abnormal morphology and decreased viability. After 1 month of
treatment prolactin levels were significantly reduced in both groups of
patients. After 6 months of treatment, a significant increase of number, total
motility, rapid progression and normal morphology was recorded in patients
treated with Cabergoline and Bromocriptine . A notable increase in the number of
erections during the first 3 months was recorded and continued throughout the 6
months of treatment. However the improvements in seminal fluid parameters and
sexual function were more evident and rapid in patients treated with
Cabergoline (Dostinex). A significant increase of serum testosterone and
dihydrotestosterone were recorded. The beginning of treatment, mild
side-effects were recorded in two patients after Caberoline usage compared to
five Bromocriptine patients who suffered mild-to-moderate
side-effects. Treatment with Cabergoline (Dostinex)
normalized prolactin levels, improving gonadal and sexual function and
fertility in males with prolactinoma, earlier than did Bromocriptine treatment.
Cabergoline provided good tolerability and excellent patient compliance to
medical treatment.
Study proves:
• Dostinex is potent in increasing libido
• Dostinex increases testosterone
• Dostinex is superior in all respects to Parlodel
• Dostinex reduces prolactin levels more than Parlodel does.
• Dostinex acts faster than Parlodel
• Dostinex side-effects are milder (if any), Parlodel side-effects are more severe and probable
Medical References
|
Cheap
Top
